Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Lyxumia, Adlyxin
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist, a type of incretin mimetic, used in the treatment of type 2 diabetes. It works by mimicking the effects of GLP-1, a naturally occurring hormone that helps regulate blood sugar levels. Lixisenatide stimulates insulin secretion when blood glucose levels are elevated, suppresses glucagon secretion, slows gastric emptying, and may promote satiety, leading to reduced food intake.
For the treatment of type 2 diabetes in conjunction with diet and exercise.
Outcome:
Increased risk of bleeding
Mechanism:
Possible alteration of warfarin metabolism
Outcome:
May affect lixisenatide absorption
Mechanism:
Delayed gastric emptying
Outcome:
May slightly affect blood glucose levels
Mechanism:
Caffeine can affect insulin sensitivity
Most likely new formulation: A once-weekly formulation of lixisenatide (Year: 2026, 75% confidence)
Based on current usage trends and clinical trial data, there is a 90% likelihood of lixisenatide remaining a viable treatment option for type 2 diabetes for the next 5 years.
Antidiabetic, GLP-1 Receptor Agonist, Incretin Mimetic
Peptide